Welcome to our dedicated page for Femto Technologies news (Ticker: BCAN), a resource for investors and traders seeking the latest updates and insights on Femto Technologies stock.
The BCAN news page aggregates historical news and press releases related to BYND Cannasoft Enterprises Inc., the Israeli-based integrated software and cannabis company that traded on Nasdaq under the symbol BCAN. These items provide context on how the company described its activities in CRM software, medical cannabis, and sexual wellness technology, as well as its later evolution into Femto Technologies Inc. as noted in SEC filings.
Readers can find coverage of capital markets transactions, including underwritten public offerings and a registered direct offering in which Aegis Capital Corp. acted as bookrunner or placement agent for BYND Cannasoft. The news flow also highlights the company’s product development milestones, such as progress on the EZ-G device, planned production agreements for the EZ-G device and capsules, and laboratory testing phases for AI-based treatment devices.
Company press releases discuss its Benefit CRM software for small and medium-sized businesses, the development of a cannabis-focused CRM platform, and licensing to engage in medical cannabis trading in Israel through agreements with licensed growers. Additional articles describe BYND Cannasoft’s intellectual property strategy, including PCT filings, provisional patent applications, and WIPO publication of the EZ-G device patent application.
Investors and observers can use this news archive to review how BYND Cannasoft communicated its plans in CRM, medical cannabis, and AI-enabled sexual wellness devices during the period when BCAN was its Nasdaq symbol, and to understand the background that preceded the later name change to Femto Technologies Inc.
BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) announced a consulting agreement with Matrix Medika to aid in the regulatory approval process for its EZ-G device. This device is a CBD-based therapeutic product aimed at the female reproductive system. Matrix Medika will provide expert opinion and market research to streamline the development process. Following the acquisition of Zigi Carmel Initiatives, BYND plans to finalize patent registration and implement a marketing strategy for the EZ-G device, focusing on both B2B and B2C sales.
BYND Cannasoft Enterprises (NASDAQ: BCAN) has received initial approval from Israel's Medical Cannabis Unit to engage in medical cannabis without direct contact with the product. This approval is part of the process for obtaining a full license to trade medical cannabis products through a licensed grower in Israel. The Israeli market has about 150,000 medical cannabis users and generates around $0.5 billion annually. BYND aims to capture 3% of this market, equating to approximately $15 million in sales within the first year of product launch.
BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) has announced an agreement to raise up to CAD$649,500 through a non-brokered private placement. The company plans to issue 150,000 common shares at a price of $4.33 each, with the proceeds earmarked for marketing and public relations expenses. The private placement is set to close by the end of October, pending regulatory approvals, and shares will be subject to a four-month hold period. This move aims to boost visibility and value for shareholders, according to CEO Yftah Ben Yaackov.
BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) announced a collaboration with the Weizmann Institute of Science to use its beta software as a service (SAAS). This includes BYND's C.R.M. System - Job Management (BENEFIT) and the CANNASOFT module for managing diverse crops. The Weizmann Institute will utilize the software free of charge for one year, after which they have the option to extend the agreement. The partnership aims to advance medical cannabis software development and generate additional revenue from software licenses.
BYND Cannasoft Enterprises (NASDAQ: BCAN) has successfully acquired Zigi Carmel Initiatives & Investments Ltd. by issuing 7,920,000 common shares valued at $37.5 million. This acquisition marks a significant step for BYND as Carmel Zigdon, the new director, is the inventor of the EZ-G device, now being commercialized. The shares allocated to Carmel are subject to a trading hold until January 23, 2023. This strategic acquisition aims to bolster BYND's market position and enhance its software offerings in the cannabis sector.
BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) discusses its operations and future outlook in a recent interview. CEO Yftah Ben Yaackov highlights the company's strategic pivot to enhance its customer relationship management (CRM) software tailored for the medical cannabis market. The company is finalizing a software solution for medical cannabis growers and has acquired a patent-pending CBD treatment device in a significant $28 million transaction. Ben Yaackov emphasizes expected growth through software development and regulatory advancements in the upcoming year.
BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) has entered a share purchase agreement to acquire Zigi Carmel Initiatives & Investments Ltd. (ZC), gaining ownership of a patent-pending CBD-based therapeutic device targeting women's health. The acquisition involves issuing 7,920,000 shares at $4.735 each and a $100,000 payment for legal expenses. The device aims to alleviate various women's health issues and is projected to enter a market expected to reach $11 billion by 2027. The transaction is set to close by October 10, 2022, pending customary conditions.
BYND Cannasoft Enterprises (NASDAQ: BCAN) has announced its acquisition of Zigi Carmel Initiatives & Investments Ltd. for 100% ownership, granting them the patent pending for the EZ-G device, designed to treat women's health issues through low-concentration CBD oils.
The transaction involves issuing 7,920,000 common shares at $4.735 each, along with a $100,000 payment for legal expenses. The company aims to finalize this acquisition by October 10, 2022, and plans to pursue regulatory approvals, patent registration, and market a unique product to address various female health concerns.